Larotrectinib

Catalog No.S5860 Synonyms: Vitrakvi, LOXO-101, ARRY-470

For research use only.

Larotrectinib (Vitrakvi, LOXO-101, ARRY-470) is an ATP-competitive, oral administered and highly selective inhibitor of the tropomyosin-related kinase (TRK) family receptors.

Larotrectinib Chemical Structure

CAS No. 1223403-58-4

Selleck's Larotrectinib has been cited by 14 publications

Purity & Quality Control

Choose Selective Trk receptor Inhibitors

Biological Activity

Description Larotrectinib (Vitrakvi, LOXO-101, ARRY-470) is an ATP-competitive, oral administered and highly selective inhibitor of the tropomyosin-related kinase (TRK) family receptors.
Targets
TRK [1]

Protocol (from reference)

Solubility (25°C)

In vitro

Chemical Information

Molecular Weight 428.44
Formula
C21H22F2N6O2
CAS No. 1223403-58-4
Storage 3 years -20°C powder
2 years -80°C in solvent

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04655404 Recruiting Drug: Larotrectinib|Procedure: Larotrectinib High Grade Glioma Nationwide Children''s Hospital April 8 2021 Early Phase 1
NCT04814667 Active not recruiting -- Solid Tumor Adult|Locally Advanced Solid Tumor|Metastatic Cancer Centre Leon Berard|Bayer February 23 2021 --
NCT04142437 Recruiting Drug: larotrectinib(Vitrakvi BAY2757556) Locally Advanced or Metastatic Solid Tumor Harboring an NTRK Gene Fusion Bayer April 3 2020 --
NCT03834961 Recruiting Drug: Larotrectinib Sulfate Central Nervous System Neoplasm|Infantile Fibrosarcoma|Recurrent Acute Leukemia|Refractory Acute Leukemia|Solid Neoplasm Children''s Oncology Group|National Cancer Institute (NCI) September 18 2019 Phase 2
NCT02637687 Recruiting Drug: Larotrectinib (Vitrakvi BAY2757556) Solid Tumors Harboring NTRK Fusion Bayer December 16 2015 Phase 1|Phase 2
NCT02576431 Recruiting Drug: BAY2757556 (Larotrectinib Vitrakvi) Solid Tumors Harboring NTRK Fusion Bayer September 30 2015 Phase 2

(data from https://clinicaltrials.gov, updated on 2022-08-01)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Larotrectinib | Larotrectinib supplier | purchase Larotrectinib | Larotrectinib cost | Larotrectinib manufacturer | order Larotrectinib | Larotrectinib distributor